In recent years, our company has strategically strengthened its presence in pharmaceutical R&D CXO industries in Heze city, Shandong province, and Shijiazhuang city, Hebei province. This expansion has given rise to two noteworthy entities: "Ruzhi Biomed" and "Diskaiwei Pharma". The establishment of these companies is aimed at providing clients with more closely tailored, high-quality services. Additionally, they operate synergistically with Chiheal Biomed, fostering a collaborative relationship with complementary advantages.

Of particular significance is the establishment of research institutes such as the Traditional Chinese Medicine Research Institute, Innovative Improvement Research Institute, and Brain Innovation Research Institute. These institutes strategically position themselves in key and unexplored areas within the CRO landscape, thereby reinforcing the high-growth potential of Chiheal Biomed in the CRO domain.

Simultaneously, our group has entered into a joint venture with Shandong Heze Pharmaceutical Port, leading to the establishment of Chiheal Pharma Factory. This specialized facility serves as a CMO/CDMO base. It is equipped with nearly 10 production lines, including comprehensive penicillin freeze-drying/water needle lines, comprehensive BFS water needle/inhalation solution lines, comprehensive BFS eye drop lines, hormone aerosol inhalation lines, anti-tumor liposome lines, anti-tumor BFS water needle lines, comprehensive pre-filled needle lines, and comprehensive oral solution/syrup lines.

This strategic move not only enhances our capability in pharmaceutical manufacturing but also aligns with our commitment to providing diversified and high-quality services across various therapeutic categories. The establishment of state-of-the-art production lines underscores our dedication to meeting the evolving needs of the pharmaceutical industry and reinforces our position as a leader in the CMO/CDMO landscape.

Our company is equipped with a sophisticated array of high-precision scientific instruments, featuring renowned brands such as Agilent, Shimadzu, and Thermo Fisher. This instrumental suite comprises more than 160 sets of High-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), and other precision instruments. This advanced instrumentation forms the backbone of our commitment to excellence in pharmaceutical R&D.

Our extensive R&D infrastructure cover a complete set of formulation equipment for APIs, peptides, tablets, injections, topical formulations, inhalable formulations, and ophthalmic drugs. This comprehensive suite underscores our dedication to addressing the diverse needs of the pharmaceutical industry across various therapeutic categories.

The company possesses end-to-end drug development capabilities, encompassing multiple dosage forms and covering the entire drug development lifecycle. This includes pre-clinical Pharmacokinetics, Pharmacodynamics, and Safety (PCC), API development, formulation Chemistry, Manufacturing, and Controls (CMC), and clinical services. Our commitment to a holistic approach in drug development positions us as a versatile and capable partner in advancing pharmaceutical innovation and meeting the highest industry standards.